Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas

Resistance to combination BRAF/MEK inhibitor (BRAFi/MEKi) therapy arises in nearly every patient with BRAF(V600E/K) melanoma, despite promising initial responses. Achieving cures in this expanding BRAFi/MEKi-resistant cohort represents one of the greatest challenges to the field; few experience addi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebecca, Vito W., Xiao, Min, Kossenkov, Andrew, Godok, Tetiana, Brown, Gregory Schuyler, Fingerman, Dylan, Alicea, Gretchen M., Wei, Meihan, Ji, Hongkai, Bravo, Jeremy, Chen, Yeqing, Fane, Mitchell E., Villanueva, Jessie, Nathanson, Katherine, Liu, Qin, Gopal, Y. N. Vashisht, Davies, Michael A., Herlyn, Meenhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882271/
https://www.ncbi.nlm.nih.gov/pubmed/36711814
http://dx.doi.org/10.1101/2023.01.20.524923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882271/
https://www.ncbi.nlm.nih.gov/pubmed/36711814
http://dx.doi.org/10.1101/2023.01.20.524923

Ejemplares similares